Topic: combination drugs

3. Vytorin

Merck’s cholesterol drugs Zetia and Vytorin are a franchise, but they’re also distinct meds with different marketing points. Zetia can be added on to any statin. Vytorin combines Zetia with Merck’s off-patent statin Zocor.

2. Zetia

Merck’s big-selling Zetia was launched in 2002, and it did gin up sales quickly; by 2005, Merck and its partner Schering-Plough was reporting $1.5 billion from Zetia. But In 2008, Zetia’s sales fell by 9% to $2.2 billion. Its sales during the final three years of its patent life hovered in the $2.5 billion range.

8. Janumet

Janumet, which combines Merck’s own blockbuster DPP-4 drug Januvia with metformin, reeled in $984 million in U.S. sales in 2016.
Januvia box

2. Januvia

Merck’s Januvia has faced its share of obstacles, but it remains a mainstay of diabetes treatment—and of Merck’s revenue mix. It brought in $3.91 billion worldwide, $2.29 billion of that in the U.S., and that doesn’t include its combo-med cousin, Janumet.